Clinical failure of CMV retinitis with intravitreal cidofovir is associated with antiviral resistance

Archives of Ophthalmology

Volumn 116, Issue 2, 1998, Pages 178-185

  Smith, Irene L ^a,b,c,d,e,f   Tashintuna, Ibrahim ^a,b,c,d,e,f   Rahhal, Firas M ^a,b,c,d,e,f   Poweli, Henry C ^a,b,c,d,e,f   Ai, Everett ^a,b,c,d,e,f   Mueller, Arthur ^a,b,c,d,e,f   Spector, Stephen A ^a,b,c,d,e,f   Freeman, William R ^a,b,c,d,e,f  

^a Departments of Pediatrics   (United States)

^b Department of Ophthalmology ^*  (United States)

^c Centers for Molecular Genetics and AIDS Research   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; GANCICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CASE REPORT; CYTOMEGALOVIRUS; DNA SEQUENCE; FEMALE; HISTOPATHOLOGY; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; LYMPHOCYTE COUNT; MALE; ORAL DRUG ADMINISTRATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELAPSE; RETINITIS; TREATMENT FAILURE; VIRUS RESISTANCE;

EID: 0031915306     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.116.2.178     Document Type: Article

References (49)

1. Kuppermann BD, Petty JG, Richman DD, et al. Cross-sectional prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with the acquired immunodeficiency syndrome: correlation with CD4t counts. Am J Ophthalmol. 1993:115:575-583.
2. Hoover DR, Peng Y, Saah A, et al. Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression. Arch Ophthalmol. 1996; 114:821-827.
3. Drew WL, Ives D, Lalezari JP, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS: Syntex Cooperative Oral Ganciclovir Study Group. NEnglJMed. 1995;333:615-620.
4. Holland GN, Buhles WC Jr, Mastre B, et al. A controlled prospective study of ganciclovir treatment for cytomegalovirus retinopathy: use of a standardized system for the assessment of disease outcome. Arch Ophthalmol. 1989;107:1759-1766.
5. Spector SA, Weingeist T, Pollard RB, et al. A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. J Infect Dis. 1993:168:557-563.
6. Spector SA, McKinley GF, Lalezari JP, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS: Roche Cooperative Oral Ganci clovir Study Group. NEnglJMed. 1996:334:1491-1497.
7. Palestine AG, Polis MA,- De Smel MO, et al. A randomized, controlled trial of f oscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med. 1991;115:665-673.
8. Jacobson MA, Causey D, Polsky B, et al. A dose ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS. JlnfectDis. 1993:168:444-448.
9. Lalezari JP, Stagg RJ, Kuppermann BD, et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. Ann Intern Med. 1997:126: 257-263.
10. Studies of Ocular Complications of AIDS (SOCA) Research Group, Freeman WR. Parenteral cidofovir for the treatment of cytomegalovirus retinitis in patients with AIDS: the HPMPC Peripheral Cytomegalovirus Retinitis Trial. Ann Intern Med. 1997:126:264-274.
11. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trial Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomega' lovirus retinitis. NEnglJMed. 1992:326:213-220.
12. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trial Group. Foscarnet-ganciclovir cytomegalovirus retinitis trial, 4: visual outcomes. Ophthalmology. 1994:101:1250-1261.
13. Drew WL, Miner RC, Busch DF, et al. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infections. J Infect Dis. 1991;163: 716-719.
14. Leport C, Puget S, Pépin J, et al. Cytomegalovirus resistant to foscarnet: clinicovirologic correlation in a patient with human immunodeficiency virus. J Infect Dis. 1993:168:1329-1330.
15. Sarasini A, Baldanti F, Furione M, et al. Double resistance to ganciclovir and foscarnet of four human cytomegalovirus strains recovered from AIDS patients. JMed Virol. 1995:47:237-244.
16. Smith IL, Flores-Aguilar M, Taskintuna I, Jiles RE, Freeman WR, Spector SA. Cytomegalovirus resistance is associated with clinical failure in AIDS patients receiving ganciclovir treatment for retinitis. In: Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology; 1996.
17. Smith IL, Cherrington JM, Jiles RE, Fuller MD, Freeman WR, Spector AS. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis. 1997; 176:69-77.
18. Baldanti F, Underwood MR, Stanat SC, et al. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J Virol. 1996:70:1390-1395.
19. Lurain NS, Thompson KD, Holmes EW, Read GS. Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents. J Virol. 1992:66:7146-7152.
20. Stanat SC, Reardon JE, Erice A, Jordan MC, Drew WL, Biron KK. Ganciclovirresistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir. Antimicrob Agents Chemother. 1991;35:2191-2197.
21. Chou S, Guentzel S, Michels KR, Miner RC, Drew WL. Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J Infect Dis. 1995:172:239-242.
22. Kirsch LS, Arevalo JF, De Clercq E, et al. Phase l/ll study of intravitreal cidofovir for the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol. 1995:119:466-476.
23. Kirsch LS, Arevalo JF, Chavez de la Paz E, et al. Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients v/ith acquired immune deficiency syndrome. Ophthalmology. 1995:102:533-543.
24. Rahhai FM, Arevalo JF, Munguia D, et al. Intravitreal cidofovir (HPMPC) for the maintenance treatment of cytomegalovirus retinitis. Ophthalmology. 1996:103: 1078-1083.
25. Rahhai FM, Arevalo JF, Chavez E, et al. Treatment of cytomegalovirus retinitis with intravitreous cidofovir in patients with AIDS. Ann Intern Med. 1996;125: 98-103.
26. Taskintuna I, Rahhal FM, Arévalo JF, et al. Low-dose intravitreal HPMPC (cidofovir) therapy of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Ophthalmology. 1997;104:1049-1057.
27. Taskintuna I, Rahhal FM, Arévalo J, Banker AS, De Clercq E, Freeman WR. Adverse events and autopsy findings after intravitreal cidofovir (HPMPC) therapy. Ophthalmology. 1997;104:1827-1836.
28. Banker AS, Gonzales C, Wiley CA, Bergeron-Lynn G, Freeman WR. The agar sandwich technique for retinal biopsy processing. Retina. 1996;16:530-534.
29. Freeman WR, Wiley CA, Gross JG, Thomas EL, Rao NA, Liggett PE. Endoretinal biopsy in immunosuppressed and healthy patients with retinitis: indications, utility and techniques. OpAtemoto 1989;96:1559-1565.
30. Schneiderman TE, Faber DW, Gross JG, Wiley CA, Freeman WR. The agaralbumin sandwich technique for processing retinal biopsy specimens. AmJOphthalmol. 1989:108:567-571.
31. Chee MS, Lawrence GL, Barrel BG. Alpha-, beta- and gamma- herpesviruses encode a putative phosphotransferase. J Gen Virol. 1989:70:1151-1160.
32. Kouzarides T, Bankier AT, Satchwell SC, Weston K, Tominson P, Barrel! BG. Sequence and transcription analysis of the human cytomegalovirus DMA polymerase gene. J Virol. 1987:61:125-133.
33. Flores-Aguilar M, Besen G, Vuong C, et al. Evaluation of retinal toxicity and efficacy of anti-CMV and anti-HSV antiviral phosphorothioate oligonucleotides ISIS 2922 and ISIS 4015. J Infect Dis. 1997;175:1308-1316.
34. Gross JG, Bozzette SA, Mathews WC, et al. Longitudinal study of cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology. 1990; 97:681-686.
35. Lurain NS, Spafford LE, Thompson KD. Mutation in the UL97 open reading frame of human cytomegalovirus strains resistant to ganciclovir. J Virol. 1994;68:44274431.
36. Baldanti F, Sarasini A, Silini E, et al. Four dually resistant human cytomegalovirus strains from AIDS patients: single mutations in UL97 and UL54 open reading frames are responsible for ganciclovir- and foscarnet-specific resistance, respectively. Scand J Infect Dis. 1995;(suppl99):103-104.
37. Hitchcock MJM, Jaffe HS, Martin JC, Stagg RJ. Cidofovir, a new agent with potent anti-herpesvirus activity. Antiviral Chem Chemother. 1996,7:115-127.
38. Davis JL, Taskintuna I, Freeman WR, Weinberg DV, Feuer WJ, Leonard RE. Iritis and hypotony after intravenous cidofovir for CMV retinitis. Arch Ophthalmol. 1997; 115:733-737.
39. Freeman WR. Intraocular antiviral therapy. Arch Ophthalmol. 1989:107:17371739.
40. Martin DF, Parks DJ, Mellow SD, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant: a randomized controlled clinical trial. Arch Ophthalmol. 1994:112:1531-1539.
41. Harada K, Eizuru Y, Isashiki Y, lhara S, Minamishima Y. Genetic analysis of a clinical isolate of human cytomegalovirus exhibiting resistance against both ganciclovir and cidofovir. Arch Virol. 1997;142:215-225.
42. Erice A, Gil-Roda C, Ferez J-L, et al. Antiviral susceptibilities and analysis of the UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J Infect Dis. 1997:175:1087-1092.
43. Tatarowicz WA, Lurain NS, Thompson KD. A ganciclovir-resistant clinical isolates of human cytomegalovirus exhibiting cross-resistance to other DNA polymerase inhibitors. J Infect Dis. 1992:166:904-907.
44. Sullivan V, Biron KK, Talarico C, et al. A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosponylmethoxyalkyl derivatives. Antimicrob Agents Chemother. 1993:37:1925.
45. Lurain NS, Thompson KD, Holmes EW, Read GS. Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents. J Virol. 1992:66:7146-7152.
46. Cherrington JM, Mulato AS, Fuller M, Chen MS. In vitro selection of a human cytomegalovirus (HCMV) that is resistant to cidofovir. In: Programs and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology; 1995.
47. Drew WL, Miner RC, Crager M, Stempien MJ. Does resistance to ganciclovir develop in patients receiving prophylactic drug? In: Programs and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology; 1995.
48. Arévalo JF, Gonzales C, Capparelli EV, et al. Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis. J Infect Dis. 1995:172:951-956.
49. Flores-Aguilar M, Kupperman BD, Quiceno Jl, et al. Pathophysiology and treatment of clinically resistant CMV retinitis. Ophthalmology. 1993:100:10221031.